Mode
Text Size
Log in / Sign up
Phase 2 N=21 Randomized Double-blind Basic Science

Driving Neuroplasticity With Nerve Stimulation and Modified CIT

Stroke · Cerebrovascular Accident

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: Change in Wolf Motor Function Test (WMFT), Timed Portion — -0.36; -0.18; -0.37; -0.15 log(seconds)

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
peripheral nerve stimulation (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
University of Kentucky
Primary completion
Feb 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Wolf Motor Function Test (WMFT), Timed Portion
-0.36; -0.18; -0.37; -0.15
SECONDARY
Change in Fugl Meyer Assessment Motor Score
10.2; 5.6; 12.5; 6.3
SECONDARY
Change in Action Research Arm Test (ARAT)
9.6; 3.67; 11.1; 4.43

Summary

The investigators proposed to evaluate the effectiveness of sustained peripheral nerve stimulation (PNS) to enhance the therapeutic effects of a modified form CIT (mCIT).

Eligibility Criteria

Inclusion Criteria

  • Chronic stroke patients
  • Single stroke
  • Chronic (more than 12 months after from stroke)
  • At least 21 years old, but there is no upper age range for this project.
  • Participants must be able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.

Exclusion Criteria

  • History of carpal tunnel syndrome and conditions that commonly cause peripheral neuropathy, including diabetes, uremia, or associated nutritional deficiencies
  • History of head injury with loss of consciousness, severe alcohol or drug abuse, psychiatric illness
  • Within 3 months of recruitment, use of drugs known to exert detrimental effects on motor recovery
  • Cognitive deficit severe enough to preclude informed consent
  • Positive pregnancy test or being of childbearing age and not using appropriate contraception
  • Participants with history of untreated depression.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02587234). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search